New scan may predict immunotherapy success in lung cancer

NCT ID NCT03564197

Completed Knowledge-focused Sponsor: The Netherlands Cancer Institute Source: ClinicalTrials.gov ↗

First seen Feb 28, 2026 · Last updated May 21, 2026 · Updated 14 times

Summary

This study tested a new type of PET scan that looks for a protein called PD-L1 in tumors. The goal was to see if this scan could predict which patients with advanced lung cancer would benefit from the immunotherapy drug nivolumab. Eighty patients received the scan before starting treatment, and researchers tracked how long their cancer stayed under control. The study aimed to improve how doctors choose treatments, not to test a new therapy itself.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC STAGE IV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Antoni van Leeuwenhoek

Amsterdam, 1060CX, Netherlands
Antonius Ziekenhuis

Utrecht, Netherlands
Deventer Ziekenhuis

Deventer, Netherlands
Jeroen Bosch Ziekenhuis

's-Hertogenbosch, Netherlands
LUMC

Leiden, Netherlands
MeanderMC

Amersfoort, Netherlands
Medisch Centrum Haaglanden

The Hague, Netherlands
VUmc

Amsterdam, 1007 MB, Netherlands

Conditions

Explore the condition pages connected to this study.

NSCLC STAGE IV